A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC

A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Direct Acting Antiviral-Post Authorization Safety Study

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)